Ongoing growth in CGT capacity

As the era of genomic medicine gains speed with the innovation of new technologies, we are at the forefront of genetic tools that can prevent, treat, or cure human diseases. It’s an exciting time, as during this early stage in developing new biological drug products, academics and industry are working closely to optimize cell and gene therapies (CGT) for a range of diseases. 
 
This has led to an increase in the demand to manufacture high-quality biologics, not to mention the analytics to characterize their release and the regulatory support to meet guidelines, as drug programs move from discovery to clinical stages.  
 
That is why it’s important to not only expand capabilities but also the capacity to serve the CGT community. As a leading partner for academics and industry, Aldevron is implementing technologies to enhance production and performance of new therapeutic modalities, and offering high-quality, standardized products to simplify the program workflow, which drives client program from early research and development to successful drug material. 
 
Furthermore, as the use and application of cell and gene therapy continues to grow, we are continually evaluating and renovating our facilities with state-of-the-art technologies, while developing new partnerships to provide the optimal capacity for process development, manufacturing and testing. As we have evolved with the CGT industry, we are dedicated to adapting and enhancing our services as the demands within the field change. 
 
To raise awareness of the need for expansion in the CDMO area, Todd Howren, PhD, VP of RNA Client Services, presented at the Outsourced Pharma Capacity Update (OPCU) - Cell and Gene event, where he highlighted Aldevron capacity and capabilities, including an update on an expansion across all facilities, providing insight into the new services that will be available due to that expansion. 
 
2023 will be an exciting year for Aldevron and biotech in general. Not only is it our 25th anniversary of serving the industry, but we’ve also expanded capacity at our facilities for plasmid, RNA, and protein manufacturing, and are building out new capabilities to service drug products to be launched later this year. Watch for more announcements on those capabilities as we celebrate our anniversary.

Watch the webinar

• Read our mRNA Production Capability announcement
• Read Todd Howren’s post on Capability versus Capacity
• Read Yasser Kehail's post on Streamlining the Drug Development Process 
• Visit our RNA - Custom Manufacturing web page
• Want to learn more? Contact Basam Barkho with your questions
• Have a topic to suggest? Let us know!